Strong Sales Growth
Net sales reached SEK 294 million, representing a 24% growth versus Q3 2024 and 34% at constant exchange rates.
Successful CERAMENT G Performance
CERAMENT G sales in the U.S. reached SEK 192 million for the quarter, showing strong traction with both new accounts and increased use among current users.
Publication of CeraHip Study
The long-awaited CeraHip study was published, marking the start of market penetration efforts in revision arthroplasty.
Robust Cash Flow and Position
The company reported strong cash generation with operating cash flow reaching SEK 71 million, leading to a cash position of SEK 379 million at the end of the quarter.
Positive Market Developments
A 6% increase in CERAMENT relevant DRG codes by CMS for orthopedics and the NTAP for CERAMENT G in open trauma were finalized.